CHARGED ALPHA
Stock Detail
CVS Unclassified Latest YouTube: Q1 2026

CVS

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Library coverage

Episodes tracked
1
Episodes linked
1
Latest video
Q1 2026
Podcast available
Yes
Current price
$93.26
-0.10 (-0.11%)
Trailing / Forward P/E
40.90x
Forward: 11.15x
Market cap / Volume
Volume:
Revenue / Earnings Growth
6.1%
Earnings: 63.1%
Margins
4.1% op
Gross: 13.4% · Net: 0.7%
Balance sheet
0.87x current
Debt / Equity: 100.9
52-week range / Beta
$58.50 - $98.43
Beta: 0.59
Analyst target
$101.88
Upside: 9.2%
Cash / shareholder return
4.37% FCF yield
Dividend yield: 2.85%

Company context

Industry: Healthcare Plans
Country: United States
Employees:
Price to book: 1.53x
Return on equity: 3.8%
CVS Health Corporation provides health solutions in the United States. The company operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPS and Medicaid health care management services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical, disease management, medical spend management services, pharmacy and other administrative services. It serves employers, insurance companies, unions, government employee groups, health plans, PDPS, Medicaid managed care plans, CMS, plans offered on public health insurance, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, personal care products, and other general merchandise products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.

Price chart

Market context for CVS

Competitive view

CVS vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

CVS
CVS
YouTube
Latest video
Q1 2026
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Balance-sheet leverage is elevated, so investors should watch refinancing costs and how much flexibility management really has.
SS&C Technologies Holdings Inc.
SSNC
YouTube
Latest video
Q1 2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Balance-sheet leverage is elevated, so investors should watch refinancing costs and how much flexibility management really has.
Charles Schwab Corporation
SCHW
YouTube
Latest video
Q1 2026
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Balance-sheet leverage is elevated, so investors should watch refinancing costs and how much flexibility management really has.
Market Cap
More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.
CVS
$118.99B
CVS
SSNC
$16.15B
SS&C Technologies Holdings Inc.
SCHW
$156.78B
Charles Schwab Corporation
Trailing P/E
Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.
CVS
40.9x
CVS
SSNC
20.8x
SS&C Technologies Holdings Inc.
SCHW
17.9x
Charles Schwab Corporation
Forward P/E
Forward P/E is often a better read on what investors are paying for the next year of earnings power.
CVS
11.2x
CVS
SSNC
8.9x
SS&C Technologies Holdings Inc.
SCHW
12.5x
Charles Schwab Corporation
Revenue Growth
Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.
CVS
6.1%
CVS
SSNC
8.8%
SS&C Technologies Holdings Inc.
SCHW
15.8%
Charles Schwab Corporation
Earnings Growth
Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.
CVS
63.1%
CVS
SSNC
8.3%
SS&C Technologies Holdings Inc.
SCHW
38.6%
Charles Schwab Corporation
Operating Margin
Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.
CVS
4.1%
CVS
SSNC
24.2%
SS&C Technologies Holdings Inc.
SCHW
49.4%
Charles Schwab Corporation
Gross Margin
Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.
CVS
13.4%
CVS
SSNC
48.0%
SS&C Technologies Holdings Inc.
SCHW
97.5%
Charles Schwab Corporation
Net Margin
Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.
CVS
0.7%
CVS
SSNC
12.7%
SS&C Technologies Holdings Inc.
SCHW
38.0%
Charles Schwab Corporation
Return on Equity
ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.
CVS
3.8%
CVS
SSNC
11.8%
SS&C Technologies Holdings Inc.
SCHW
19.1%
Charles Schwab Corporation
Free Cash Flow Yield
Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.
CVS
4.4%
CVS
SSNC
7.9%
SS&C Technologies Holdings Inc.
SCHW
6.2%
Charles Schwab Corporation
Debt to Equity
Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.
CVS
100.91x
CVS
SSNC
110.67x
SS&C Technologies Holdings Inc.
SCHW
120.77x
Charles Schwab Corporation
Current Ratio
A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.
CVS
0.87x
CVS
SSNC
1.10x
SS&C Technologies Holdings Inc.
SCHW
0.63x
Charles Schwab Corporation
Beta
Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.
CVS
0.59
CVS
SSNC
1.12
SS&C Technologies Holdings Inc.
SCHW
0.80
Charles Schwab Corporation
Dividend Yield
Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.
CVS
2.9%
CVS
SSNC
1.6%
SS&C Technologies Holdings Inc.
SCHW
1.2%
Charles Schwab Corporation
Analyst Upside
Higher analyst upside suggests the Street still sees room between current price and consensus fair value.
CVS
9.2%
CVS
SSNC
41.4%
SS&C Technologies Holdings Inc.
SCHW
28.5%
Charles Schwab Corporation

Episode timeline

Episode archive for CVS

Each row is one earnings episode with every verified platform link available.

Q1 2026
Episode live
Published youtube podcast complete
CVS Stock: Record $100.4B Revenue — Q1 2026
Quarterly earnings-analysis entry for CVS. Use the links on the right to open the video or podcast episode.